Serge Belanger
analystMale0.0Global Dominance: 0.00%
Serge Belanger is an analyst at Needham & Co., specializing in biotechnology investments. He has commented on the financial implications of azetukalner's potential market price, highlighting the challenges patients like Rick Bishop may face in affording the medication once it is commercially available.
Power0
Reach0
Collect
Not in the pool (under ¢1).
Recent news mentions
Needham & Co. analyst Serge Belanger mentioned that Mr. Bishop’s medical bills have wiped out his retirement savings already.
Xenon awaiting critical epilepsy drug study results that could lead to FDA approvalThe Globe and Mail·
Canada· 2026-03-02
Canada· 2026-03-02
